Brown Advisory Inc. Reduces Stock Position in Illumina, Inc. $ILMN

Brown Advisory Inc. lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 589,173 shares of the life sciences company’s stock after selling 28,210 shares during the quarter. Brown Advisory Inc.’s holdings in Illumina were worth $77,276,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in ILMN. Capital World Investors boosted its holdings in shares of Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after acquiring an additional 3,331,542 shares during the last quarter. Morgan Stanley boosted its holdings in shares of Illumina by 66.0% during the 4th quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after acquiring an additional 1,005,474 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after acquiring an additional 911,843 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in shares of Illumina during the 4th quarter valued at about $73,532,000. Finally, Norges Bank purchased a new stake in shares of Illumina during the 4th quarter valued at about $70,844,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In other Illumina news, CAO Scott D. Ericksen sold 500 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the sale, the chief accounting officer owned 14,446 shares in the company, valued at approximately $2,311,360. This trade represents a 3.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the sale, the senior vice president owned 21,259 shares in the company, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,003,154 shares of company stock worth $155,600,208 in the last 90 days. Insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ILMN shares. JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and raised their price target for the company from $125.00 to $185.00 in a report on Wednesday, June 10th. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Guggenheim increased their price objective on shares of Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Barclays increased their price objective on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research note on Friday, May 1st. Finally, Canaccord Genuity Group lowered their price objective on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $142.13.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $160.97 on Monday. The firm’s 50 day moving average price is $141.65 and its 200-day moving average price is $135.05. Illumina, Inc. has a twelve month low of $85.77 and a twelve month high of $177.22. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $24.35 billion, a PE ratio of 29.27, a price-to-earnings-growth ratio of 3.02 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the business earned $0.97 EPS. The firm’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts expect that Illumina, Inc. will post 5.21 EPS for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.